OBJECTIVES: To review a contemporary approach to the management of patients with
cardiogenic shock (CS). DATA SOURCES: We reviewed salient medical literature regarding …

Cardiogenic shock (CS) is characterized by low cardiac output and sustained tissue
hypoperfusion that may result in end-organ dysfunction and death. CS is associated with …

and management remains challenging despite advances in therapeutic options. CS is
caused by severe impairment of myocardial performance that results in diminished cardiac …

Cardiogenic shock (CS) is a leading cause of mortality associated with acute myocardial
infarction (AMI). 1, 2 Improved prehospital emergency care and timely reperfusion from …

Cardiogenic shock mortality has not changed in a significant way in many years. Recent
advances such as more granular assessment of shock severity have the potential to improve …

In recent years, there have been significant advancements in the understanding, risk-
stratification, and treatment of cardiogenic shock (CS). Despite improved pharmacologic and …

OBJECTIVES: Cardiogenic shock presents with variable severity. Categorizing cardiogenic
shock into clinical stages may improve risk stratification and patient selection for therapies …

Cardiogenic shock (CS) is a complex multifactorial clinical syndrome with extremely high
mortality, developing as a continuum, and progressing from the initial insult (underlying …

Mortality in cardiogenic shock remains high. Overall, these findings highlight the need to
address the lack of effective treatments in this field, particularly for cardiogenic shock caused …

Aim: Evidence on non-ischemic cardiogenic shock (CS) is scarce. The aim of this study was
to investigate differences in patient characteristics, use of treatments and outcomes in …